Is Blueprint Medicines Corp (BPMC) Stock About to Get Hot Thursday?

Blueprint Medicines Corp (BPMC) stock is down 8.48% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Blueprint Medicines Corp has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on BPMC!

See Full BPMC Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With BPMC Stock Today?

Blueprint Medicines Corp (BPMC) stock is trading at $63.81 as of 11:54 AM on Thursday, Aug 18, a rise of $2.64, or 4.31% from the previous closing price of $61.17. The stock has traded between $60.90 and $66.27 so far today. Volume today is light. So far 592,215 shares have traded compared to average volume of 927,707 shares.

More About Blueprint Medicines Corp

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants. Click Here to get the full Stock Report for Blueprint Medicines Corp stock.